Henry Schein, Inc. $HSIC Shares Bought by Clarkston Capital Partners LLC

Key Points

• Clarkston Capital Partners LLC increased its holdings in Henry Schein, Inc. by 0.4%, now owning 1,751,570 shares, which represents 2.4% of its investment portfolio.
• Henry Schein reported $1.10 earnings per share for the last quarter, missing the consensus estimate of $1.19, although revenue increased by 3.3% year-over-year, totaling $3.24 billion.
• Analysts have reduced their price targets on Henry Schein's stock, with a current consensus target of $75.58 and a rating of "Hold" from multiple firms.

Clarkston Capital Partners LLC raised its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 0.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,751,570 shares of the company's stock after purchasing an additional 7,345 shares during the period. Henry Schein accounts for approximately 2.4% of Clarkston Capital Partners LLC's investment portfolio, making the stock its 15th biggest holding. Clarkston Capital Partners LLC owned about 1.44% of Henry Schein worth $119,965,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HSIC. Investment Management Corp VA ADV acquired a new stake in Henry Schein in the fourth quarter worth about $32,000. Rakuten Securities Inc. acquired a new stake in shares of Henry Schein in the first quarter worth $34,000. Whittier Trust Co. raised its holdings in shares of Henry Schein by 714.3% during the first quarter. Whittier Trust Co. now owns 798 shares of the company's stock worth $55,000 after purchasing an additional 700 shares during the last quarter. UMB Bank n.a. lifted its position in Henry Schein by 23.2% during the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock valued at $73,000 after purchasing an additional 201 shares during the period. Finally, Allworth Financial LP boosted its holdings in Henry Schein by 24.5% in the first quarter. Allworth Financial LP now owns 1,178 shares of the company's stock valued at $78,000 after purchasing an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

Henry Schein Stock Up 1.5%

Henry Schein stock traded up $1.00 during trading on Tuesday, reaching $69.47. The stock had a trading volume of 684,906 shares, compared to its average volume of 1,761,254. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The stock has a market cap of $8.42 billion, a PE ratio of 22.41, a P/E/G ratio of 2.30 and a beta of 0.81. The business has a 50 day moving average price of $70.51 and a 200 day moving average price of $70.23.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing analysts' consensus estimates of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HSIC shares. Wells Fargo & Company decreased their price objective on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Piper Sandler cut their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Robert W. Baird restated a "neutral" rating and set a $72.00 price target (down previously from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $80.00 to $76.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Finally, UBS Group lowered their target price on Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $76.67.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.